Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.86 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.86 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.86 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.86 |
| ▸ | NSD2 | O96028 | 1/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.86 |
| ▸ | BID | P55957 | 1/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.86 |
| ▸ | ASPH | Q12797 | 1/20 | 0.86 |
| ▸ | BAD | Q92934 | 1/20 | 0.86 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.86 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.86 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16038850 | 1.00 | BCL2 (0.86) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16039937 | 1.00 | BCL2 (0.86) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL20184272 | 0.95 | BCL2 (0.82) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL30314032 | 0.95 | BCL2 (0.90) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1699850 | 0.95 | BCL2 (0.90) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16037497 | 0.95 | BCL2 (0.90) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL30298472 | 0.95 | BCL2 (0.90) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16038722 | 0.95 | BCL2 (0.90) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16037650 | 0.94 | BCL2 (0.85) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL19424448 | 0.94 | BCL2 (0.78) | BCL2BCL2L1MCL1BCL2L2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403467-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2021-12-30 | — | — | US | claimed |
| US-20200331907-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2020-10-22 | — | — | US | claimed |
| EP-3415514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2018-12-19 | — | — | EP | claimed |
| US-20170008891-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2017-01-12 | — | — | US | claimed |
| EP-2970257-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| US-20150299197-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2015-10-22 | — | — | US | claimed |
| WO-2014158528-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140275082-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2014-09-18 | — | — | US | claimed |
| US-20210403467-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2021-12-30 | — | — | US | disclosed |
| CN-107987075-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2020-12-01 | — | — | CN | disclosed |
| US-20200331907-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3415514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180354952-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2018-12-13 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170008891-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2017-01-12 | — | — | US | disclosed |
| EP-2970257-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150299197-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2015-10-22 | — | — | US | disclosed |
| WO-2014158528-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275082-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | BCL2 520/4885BCL2L1 953/4885MCL1 137/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | BCL2 132/4885BCL2L1 464/4885MCL1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.